Journal: Journal of Cancer
Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker
doi: 10.7150/jca.64082
Figure Lengend Snippet: Comparison of the levels of CXCL12, CXCR4, and FAPα by immunohistochemical staining among pathways in locally advanced rectal cancer (LARC) after neoadjuvant chemoradiotherapy (nCRT) (LARC-nCRT) (n = 61), LARC untreated with nCRT (LARC-no nCRT) (n = 60) and high-grade dysplasia of colorectal adenoma (HD) (n = 16). The levels of the three proteins were higher in LARC-nCRT than in LARC-no nCRT or HD (p < 0.001 for each). (A) CXCL12 positivity: 62.3%, 38/61 LARC-nCRT cases; 5.0%, 3/60 LARC-no nCRT cases; and 0.0%, 0/16 HD cases. (B) CXCR4 positivity: 47.5%, 29/61 LARC-nCRT cases; 0.0%, 0/60 LARC-no nCRT cases; and 0.0%, 0/16 HD cases. (C) FAPα positivity: 62.3%, 38/61 LARC-nCRT cases; 25.0%, 15/60 LARC-no nCRT cases; and 0.0%, 0/16 HD cases.
Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).
Techniques: Comparison, Immunohistochemical staining, Staining